Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.

Frailty after kidney transplantation is a harbinger for death and other major adverse outcomes in hospitalized patients. The hospital frailty risk score (HFRS) predicts graft failure, severe infection ...

Almost half of patients hospitalized for acute heart failure in Europe are readmitted within a year, according to a new study led by researchers at Karolinska Institutet and published in the European ...